Iterum Therapeutics plc, a company dedicated to developing next-generation antibiotics, announced an extension of the term of their $20 million promissory note owed to Pfizer Inc. The due date for this regulatory milestone payment, associated with the FDA approval of ORLYNVAH™, has been extended from October 2026 to October 2029. In connection with this extension, the annual interest rate on the note will increase from 8% to 10% starting in October 2026. This extension allows Iterum to strategically invest capital from ORLYNVAH™ sales to support its market launch and expansion efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.